Cohort demographics and phenotypes
| Total no of patients | 100 |
| Age (years), mean (range) | 60.4 (22–87) |
| Male | 54% |
| Female | 46% |
| Site of first muscle weakness | |
| Upper limb | 40% |
| Lower limb | 39% |
| Bulbar | 19% |
| Respiratory | 1% |
| Trunk | 1% |
| Disease subtype | |
| ALS | 83% |
| LMN predominant | 12% |
| UMN predominant | 5% |
| Family history of ALS | 7% |
| Time from onset of first muscle weakness (months), mean (SD, range) | 20.8 (20.4, 1–134) |
| Time from onset of first muscle weakness until death (months), mean (SD, range)* | 28.5 (21.0, 7–85) |
| ALSFRS-R, mean (range) at first assessment | 36.9 (15–47) |
| Revised El-Escorial criteria at first assessment | |
| Clinically probable laboratory supported | 36% |
| Clinically probable | 30% |
| Clinically suspected | 15% |
| Clinically definite | 13% |
| Clinically possible | 6% |
ALS, amyotrophic lateral sclerosis; ALSFRS-R, revised ALS-Functional Rating Score; LMN, lower motor neuron; UMN, upper motor neuron.